Scotland Advises Tysabri Use In Highly Active Relapsing Remitting Multiple Sclerosis
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) welcome the recent announcement by the Scottish Medicines Consortium (SMC) advising the use of TYSABRI® (natalizumab) in people with highly active relapsing remitting multiple sclerosis (RRMS).

















